Daratumumab and hyaluronidase-fihj: On May 1, 2020, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex) for adult patients with newly diagnosed or relapsed or refractory multiple myeloma.
Ibrutinib: On April 21, 2020, the FDA expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Isatuximab-irfc: On March 2, 2020, the FDA approved isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies.
Acalabrutinib: On November 21, 2019, the FDA approved acalabrutinib (Calquence) for adults with CLL or SLL.
Zanubrutinib: On November 14, 2019, the FDA approved zanubrutinib (Brukinsa) for adult patients with mantle cell lymphoma who have received at least one prior therapy.